Cargando…
A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer
BACKGROUND: The current National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer (NSCLC) recommend that surgeons sample is not clear. We aimed to define a minimal number of examined lymph nodes for removal or sampling for optimized nodal staging recommendation, with a f...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947406/ https://www.ncbi.nlm.nih.gov/pubmed/33718024 http://dx.doi.org/10.21037/tlcr-20-1024 |
_version_ | 1783663219550715904 |
---|---|
author | Zhu, Zhihua Song, Zhengbo Jiao, Wenjie Mei, Weijian Xu, Chunwei Huang, Qinghua An, Chaolun Shi, Jianguang Wang, Wenxian Yu, Guiping Sun, Pingli Zhang, Yinbin Shen, Jianfei Song, Yong Qian, Jun Yao, Wang Yang, Han |
author_facet | Zhu, Zhihua Song, Zhengbo Jiao, Wenjie Mei, Weijian Xu, Chunwei Huang, Qinghua An, Chaolun Shi, Jianguang Wang, Wenxian Yu, Guiping Sun, Pingli Zhang, Yinbin Shen, Jianfei Song, Yong Qian, Jun Yao, Wang Yang, Han |
author_sort | Zhu, Zhihua |
collection | PubMed |
description | BACKGROUND: The current National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer (NSCLC) recommend that surgeons sample is not clear. We aimed to define a minimal number of examined lymph nodes for removal or sampling for optimized nodal staging recommendation, with a focus on T(1–3)N(0)M(0) patients. METHODS: A total of 55,101 consecutive patients were selected, including 52,099 patients with US Surveillance, Epidemiology, and End Results (SEER) data and 3,002 patients in a Chinese multicenter database from 11 thoracic referral centers, who underwent complete resection plus lymph node dissection or sampling for stage T(1–3)N(0)M(0) NSCLC. Propensity score-matching analysis was performed with R software, and a cut-off value was calculated using X-tile software. Survival was evaluated using the Kaplan-Meier method and Cox proportional hazard models. RESULTS: Five-year survival rates with respect to total examined lymph nodes numbers (examined lymph nodes <10 vs. examined lymph nodes ≥10) were 69% and 64% (group A), 66% and 63% (group B), 62% and 58% (group C), 81% and 75% (group D). There were significant differences between examined lymph nodes <10 and examined lymph nodes >10 in each group (P<0.001). CONCLUSIONS: A minimum of 10 examined lymph nodes would significantly improve T(1–3)N(0)M(0) NSCLC prognosis and patients’ survival rates if implemented as a minimum standard for lymphadenectomy. Therefore, we recommended a minimum of 10 examined lymph nodes for T(1–3)N(0)M(0) patients. |
format | Online Article Text |
id | pubmed-7947406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-79474062021-03-12 A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer Zhu, Zhihua Song, Zhengbo Jiao, Wenjie Mei, Weijian Xu, Chunwei Huang, Qinghua An, Chaolun Shi, Jianguang Wang, Wenxian Yu, Guiping Sun, Pingli Zhang, Yinbin Shen, Jianfei Song, Yong Qian, Jun Yao, Wang Yang, Han Transl Lung Cancer Res Original Article BACKGROUND: The current National Comprehensive Cancer Network (NCCN) guidelines for non-small cell lung cancer (NSCLC) recommend that surgeons sample is not clear. We aimed to define a minimal number of examined lymph nodes for removal or sampling for optimized nodal staging recommendation, with a focus on T(1–3)N(0)M(0) patients. METHODS: A total of 55,101 consecutive patients were selected, including 52,099 patients with US Surveillance, Epidemiology, and End Results (SEER) data and 3,002 patients in a Chinese multicenter database from 11 thoracic referral centers, who underwent complete resection plus lymph node dissection or sampling for stage T(1–3)N(0)M(0) NSCLC. Propensity score-matching analysis was performed with R software, and a cut-off value was calculated using X-tile software. Survival was evaluated using the Kaplan-Meier method and Cox proportional hazard models. RESULTS: Five-year survival rates with respect to total examined lymph nodes numbers (examined lymph nodes <10 vs. examined lymph nodes ≥10) were 69% and 64% (group A), 66% and 63% (group B), 62% and 58% (group C), 81% and 75% (group D). There were significant differences between examined lymph nodes <10 and examined lymph nodes >10 in each group (P<0.001). CONCLUSIONS: A minimum of 10 examined lymph nodes would significantly improve T(1–3)N(0)M(0) NSCLC prognosis and patients’ survival rates if implemented as a minimum standard for lymphadenectomy. Therefore, we recommended a minimum of 10 examined lymph nodes for T(1–3)N(0)M(0) patients. AME Publishing Company 2021-02 /pmc/articles/PMC7947406/ /pubmed/33718024 http://dx.doi.org/10.21037/tlcr-20-1024 Text en 2021 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Zhu, Zhihua Song, Zhengbo Jiao, Wenjie Mei, Weijian Xu, Chunwei Huang, Qinghua An, Chaolun Shi, Jianguang Wang, Wenxian Yu, Guiping Sun, Pingli Zhang, Yinbin Shen, Jianfei Song, Yong Qian, Jun Yao, Wang Yang, Han A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer |
title | A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer |
title_full | A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer |
title_fullStr | A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer |
title_full_unstemmed | A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer |
title_short | A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer |
title_sort | large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947406/ https://www.ncbi.nlm.nih.gov/pubmed/33718024 http://dx.doi.org/10.21037/tlcr-20-1024 |
work_keys_str_mv | AT zhuzhihua alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT songzhengbo alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT jiaowenjie alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT meiweijian alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT xuchunwei alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT huangqinghua alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT anchaolun alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT shijianguang alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT wangwenxian alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT yuguiping alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT sunpingli alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT zhangyinbin alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT shenjianfei alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT songyong alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT qianjun alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT yaowang alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT yanghan alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT alargerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT zhuzhihua largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT songzhengbo largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT jiaowenjie largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT meiweijian largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT xuchunwei largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT huangqinghua largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT anchaolun largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT shijianguang largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT wangwenxian largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT yuguiping largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT sunpingli largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT zhangyinbin largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT shenjianfei largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT songyong largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT qianjun largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT yaowang largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT yanghan largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer AT largerealworldcohortstudyofexaminedlymphnodestandardsforadequatenodalstaginginearlynonsmallcelllungcancer |